Note: Descriptions are shown in the official language in which they were submitted.
CA 02829687 2015-01-22
New crystalline form VII of agomelatine, preparation method and use thereof
and pharmaceutical composition containing same
Technical field
The present invention relates to a new crystalline form of agomelatine, N-[2-
(7-
methoxy-1-naphthyl)ethyl]acetamide, its method of preparation, application and
pharmaceutical compositions.
Prior art
Agomelatine, with chemical name N42-(7-methoxy- 1 -naphthyl)ethyl]acetamide
and brand name Valdoxan, has the following chemical structure (I):
0
Me0
(i)
It has a dual effect, acting not only as an agonist of melatoninergic system
receptors, but also as an antagonist of the 51-IT2c receptor. Its properties
mean that it
is active in the central nervous system, especially in the treatment of severe
depression, seasonal affective disorder, sleep disorders, cardiovascular
diseases,
digestive system diseases, insomnia and fatigue brought on by jet lag, eating
disorders and obesity. Agomelatine is the first melatoninergic antidepressant,
and is
effective in the treatment of depression and the improvement of sleep
parameters,
while not affecting sexual function.
The preparation and therapeutic use of agomelatine have been reported in the
European patent EP0447285.
In view of the pharmaceutical value of the said compound, it is important to
obtain
a highly pure, stable crystalline form with good reproducibility in order for
it to be
advantageous in pharmaceutical preparation and stable enough for long-term
storage
without having specific requirements in terms of temperature, light, humidity
or
oxygen levels.
The Chinese patents CN1680284, CN1907959, CN1907957, CN1907958,
CN101585779, CN101781226 have made public the various crystalline forms as
well as the preparation methods of agomelatine.
Among these, crystalline form II is prepared by recrystallization from ethanol
and
water. Crystalline form III is prepared by heating agomelatine to 110 C until
complete melting occurs and then slowly cooling down until crystallization
takes
place. Crystalline form IV is prepared by heating agomelatine at 110 C until
complete melting occurs and then rapidly cooling down to 50-70 C and
maintaining
a temperature f 70 C for approximately 5 hours until crystallization
CA 02829687 2013-09-10
occurs; crystalline form V is prepared by the so-called "high energy"
mechanical
grinding of agomelatine, while crystalline form VI is obtained through
recrystallization from acetic acid and water.
It is well known that chemical compounds can display different molecular
arrangements, and possess different solid forms, i.e. there are many
crystalline
forms of the same compound. Among pharmaceuticals, different crystalline forms
can lead to differences in dissolution and bioavailability. Therefore in
pharmaceutical development it is particularly important to search for
crystalline
structures that are highly pure, offer good reproducibility, are easy to
produce and
use, and with excellent dissolution and bioavailability.
Scope of the Invention
The aim of the present invention is to provide a new crystalline form of
agomelatine, i.e. crystalline form VII, while also providing a preparation
process
for the crystalline form of agomelatine. When compared with crystalline form
II
of the currently available Valdoxan, the said new crystalline form offers
valuable
characteristics and a preparation method having good reproducibility.
The crystalline form VII of agomelatine in the present invention may be used
in
the treatment of diseases of the melatoninergic system, sleep disorders,
stress,
anxiety, seasonal affective disorder, severe depression, cardiovascular
diseases,
digestive system diseases, insomnia and fatigue brought on by jet lag,
schizophrenia, phobias, and depression.
The present invention also aims to provide a method of preparation for the
crystalline form VII of agomelatine which is simple in its operation and
offers
good reproducibility.
A further aim of the present invention is to provide a pharmaceutical
composition, which includes the crystalline form VII of agomelatine of this
invention as well as pharmaceutically acceptable adjuvants or excipients.
The said pharmaceutical composition can be configured to be used in different
application routes, especially when administered either orally or via
injection.
According to the nature and severity of the illness, treatment may be
administered via a regulated dosage based on the age and weight of the
patient.
The dosage may vary between 0.1 mg and 1 g per day, being administered once
only or several times.
The following examples of X-ray diffraction diagrams of the crystalline form
of agomelatine of the present invention use Bragg angle 20, interplanar
crystal
spacing d and relative intensity to show:
20 d(A) Relative intensity (I%)
10.557 8.3725 32.35
13.301 6.6509 11.45
16.145 5.4855 10.60
2
CA 02829687 2015-01-22
17.286 5.1258 6.19
17.841 4.9675 100.00
19.359 4.5813 10.83
20.089 4.4164 11.77
23.366 3.8040 29.82
24.944 3.5667 21.60
26.128 3.4078 12.47
When using X-ray diffraction to measure the crystallization of the present
invention, sometimes owing to the measurement equipment or test conditions,
the
measured peaks show slight deviations in measurement; more specifically, for
example there may be a deviation in measurement of the 20 value by
approximately
0.2; even if extremely accurate equipment is used, a deviation of
approximately
0.1 may be seen. As a result, this deviation must be taken into consideration
when
determining each crystalline structure.
XRD test conditions:
Instrument model: Bruker D8 ADVANCETM X-ray diffractometer
Experiment parameters:
Detector: LynxEye detector
Light source: CuKa 40 kV 40 mA
Monochromator: Ni filter disc
Divergence slit: 1
DivH.L.Slit: 1.0 mm
Probe: LynxEye probe
Scanning method: 0-0 continuous scanning
Scanning range: 3 -45
Step length: 0.02
Scanning speed: 8.0 /min
Scanning time: 5 min
Scanning temperature: Room temperature
DSC test conditions:
Instrument model: NETZSCH DSC 204F1
Experimental conditions:
Crucible type: Standard aluminium crucible (perforated)
Sweep gas: high purity nitrogen 20 ml/min; shielding gas: high purity
nitrogen 60 ml/min.
Temperature range: Room temperature-140 C
Heating rate: 10 C/min
TGA test conditions
Instrument model: NETZSCH TG 209F1
3
CA 02829687 2013-09-10
Experimental conditions:
Crucible type: A1203
Sweep gas: N2 20 ml/min; shielding gas: N2 10 ml/min
Temperature range: Room temperature-300 C
Heating rate: 10 C/min
The method of preparation of the crystalline form VII of the present invention
involves dissolving agomelatine compounds of formula (II) or (III) in acetic
acid,
to which acetate is then added (preferably potassium acetate or ammonium
acetate). Water is then added dropwise to this reaction mixture and agitated
at a
temperature of 17-23 C in order to bring about crystallization, with the
crystals
then being separated from the solution.
0 0
N)CH3
Me0 Me0
.HCI.H20 .HBr.H20
(II) (III)
In the present invention as described, there are no special requirements in
terms
of the amount of acetic acid that is to be added as long as a sufficient
amount is
used to dissolve the raw materials, while heating can also be suitably applied
to
facilitate dissolution.
The molar ratio of agomelatine compounds of form (II) or (III) and acetate is
preferably in the order of 1 : 1-1.5, most optimally 1 : 1-1.1. The said
acetate
comprises potassium acetate and ammonium acetate.
In the preparation method of the present invention as described, the ratio of
volume of acetic acid to water is 1:10-30.
In a preferred embodiment of the preparation method for the crystalline form
VII in the present invention, when the temperature of the resulting reaction
mixture reaches 19-25 C, and in particular when around 22 C or 23 C, water is
added dropwise in order to bring about crystallization.
In a further preferred embodiment, when water is added dropwise to the
resulting reaction mixture, agitation then occurs at a temperature of around
20 C.
This may take place over a period of around 2 hours in order to bring about
crystallization.
In another preferred embodiment, following the addition of acetate, the
reaction
mixture is heated to 30-50 C, resulting in a clear solution; the said solution
is then
left to cool on its own, and water is added dropwise in order to bring about
crystallization.
The present invention results in a new crystalline form VII of agomelatine,
with
high purity, stable crystalline form and good reproducibility making it easy
to
4
CA 02829687 2015-01-22
mass-produce, thus possessing advantages in production. Compared to the
currently
available crystalline forms, it possesses the qualities of good stability and
solubility.
According to Chinese patent applications CN 102190594 and CN 102190595,
agomelatine compounds of formula (II) or (III) as previously described may be
produced by means of the following preparation method, where the said
preparation
method involves reacting agomelatine with various forms of HC1 or HBr in order
to
form a hydrate. The two methods are as follows: Agomelatine is firstly
dissolved in a
water-containing organic solvent, after which either HC1 or HBr gas is added,
the
solid crystals are washed and then dried; or else agomelatine is added to a
solvent
containing HC1 or HBr, and the solid crystals are then washed and dried. If
the first
method is used, an overabundance of HC1 or HBr may lead to a decrease in
yield,
while in the second method the amount of HC1 and HBr present in the solvent is
easily controlled. Therefore the second method is preferred.
Specifically, agomelatine may be added to a water-containing organic solvent,
followed by the addition of a solvent containing HC1 or HBr dropwise. The
solid
crystals are then washed and then dried.
Likewise, it is also possible to add agomelatine to an organic solvent,
followed by
the addition of an aqueous solution containing HC1 or HBr dropwise. The solid
crystals are then washed and then dried.
The full contents of reference documents either quoted or mentioned in this
application have been referenced.
Description of drawings
Figure 1 shows the X-ray diffraction of the crystalline form VII in embodiment
1
of the present invention;
Figure 2 shows the DSC change in heat absorption of the crystalline form VII
in
embodiment 1 of the present invention;
Figure 3 shows the thermogravimetric analysis TGA curve of the product in
embodiment 5 of the present invention;
Figure 4 shows the thermogravimetric analysis TGA curve of the product in
embodiment 6 of the present invention.
Details of the embodiments
The following embodiments further describe the present invention but do not
limit
the scope thereof.
Embodiment 1:
7.6g of agomelatine compound of formula (III) is dissolved in 19m1 of
AcOH, to which 3.5g of KOAc is added; the mixture is then heated to 40 C,
resulting in a clear solution; this is then left to cool on its own, gradually
becoming
turbid. When the temperature reaches 22 C, 250m1 water is added dropwise. At a
CA 02829687 2013-09-10
temperature of ¨20 C, agitation is carried out over 2 hours, followed by
filtration,
then washing and drying the filter cake at 50 C under vacuum until constant
weight is achieved, resulting in 4.5g of white solid, purity: 99.8%, melting
point:
98-100 C.
Embodiment 2:
2g of agomelatine compound of formula (II) is dissolved in 5m1 of AcOH, to
which 0.57g of NH40Ac is then added; the mixture is then heated to 40 C,
resulting in a clear solution; this is then left to cool on its own, gradually
becoming turbid; when the temperature reaches 22 C, 150m1 of water is added
dropwise, and at a temperature of ¨20 C, agitation is carried out over 2
hours,
followed by filtration, then washing and drying the filter cake at 50 C under
vacuum until constant weight is achieved, resulting in 1.4g of white solid,
purity:
99.7%, melting point: 98-100 C.
Embodiment 3:
40g of agomelatine compound of formula (III) is dissolved in 130m1 of AcOH,
to which 1 Og of NH40Ac is then added; the mixture is then heated to 40 C,
resulting in a clear solution; this is then left to cool on its own, gradually
becoming turbid; when the temperature reaches 23 C, 2.6L of water is added
dropwise, and at a temperature of ¨20 C, agitation is carried out over 2
hours,
followed by filtration, then washing and drying the filter cake at 50 C under
vacuum until constant weight is achieved, resulting in 25g of white solid,
purity:
99.8%, melting point: 98-100 C.
Embodiment 4:
Crystalline forms II, III, VI and VII (obtained through embodiment 3) are each
placed in thermostatic containers at a temperature of 40 C and stored for 20
days,
with the stability of these crystalline samples being studied using the method
of
High Performance Liquid Chromatography.
1. Purity measurement of the sample
Chromatographic conditions: Octadecyl silane chemically bonded silica is used
as packing; a mixed solution of 10 mmol/L phosphate buffer (adjusted to pH 7.0
with sodium hydroxide) and acetonitrile in the ratio 2:7 by volume acts as the
mobile phase; column temperature 40 C; and detection wavelength 220nm. Purity
is measured using an internal standard method.
In the mobile phase, crystalline forms II, III, VI and VII are distributed
into
lmg/mL solutions, 10 I, of each of which are then passed into a liquid
chromatograph, with their chromatograms being recorded.
6
CA 02829687 2013-09-10
2. Assay of the Sample
The reference sample purity measurement method was used, with
measurements being made using an external standard method, the results are
shown in Table I.
Table I
Sample name Crystalline form Crystalline form
Crystalline form Crystalline form
1! 111 VI VII
Purity Content Purity Content Purity Content Purity Content
Before storage 99.7% 99.5% 99.9% 99.5% 99.7% 99.3% 99.8% 99.8%
After storage in 99.3% 99.6% 99.3% 99.4% 99.6% 99.1% 99.7% 99.6%
the
thermostatically
controlled
containers for
20 days
3. Measurement of water solubility
The HPLC method was used to determine water solubility, with measurements
being made using an external standard method. The results are shown in Table
II.
Table II
Sample name = Crystalline form II
Crystalline form VI Crystalline form VII
Solubility (mg/ml) 0.301 0.336 0.330
4. Determination of crystalline stability
Measured using the pharmacopoeia stability assessment method:
1) Influencing factor testing (exposed for 10 days): high temperature (60 C),
illumination (45001x), high humidity (92.5%RH, 25 C)
2) Accelerated testing (hermetically sealed for 6 months): temperature 40 C,
humidity 75%RH
3) Long term testing (hermetically sealed for 12 months): temperature 25 C,
humidity 60%RH
7
CA 02829687 2013-09-10
Table III
Sample name Crystalline form II
Crystalline form VI Crystalline form VII
Influencing High -\/* x* \i
factor temperature
Illumination
High Ai Ai .\i
humidity
Accelerated testing Ai Ai Ai
Long term testing (6 Ai Ai -\I
months)
Long term testing (9 -\/ Ai Ai
months)
Long term testing (12 -\.1 x Ai
months)
*: -\/- stable; x- unstable
As can be seen from the test results, in its preparation process, the
stability and
purity of the new crystalline form VII of agomelatine clearly offers
advantages
when compared with currently available crystalline forms, especially in
pharmaceutical production.
5. Study into the stability of pharmaceutical compositions (crystalline form,
purity and content)
The product (obtained via embodiment 7) was subjected to the pharmacopoeia
stability assessment method and underwent influencing factor testing (10 day
exposure): High temperature (40 C), illumination (45001x), high humidity
(92.5%RH, 25 C); Accelerated testing (hermetically sealed for 6 months):
temperature 40 C, humidity 75%RH; Long term testing (hermetically sealed for
8 months): temperature 25 C, humidity 60%RH. The assessment results
demonstrate that under the above conditions neither the crystalline form,
purity
nor content of the product underwent any changes.
Consequently, the test results of the pharmaceutical ingredients and capsules
of
this product indicate that form VII has a great potential in pharmaceutical
production.
Embodiment 5: Agomelatine compound of formula (II)
10g of agomelatine is added to a 100m1 solution of ethyl acetate. At a
temperature of 10 C, 4.6g of an aqueous solution of HC1 (36%) is slowly added
dropwise. Agitation is then carried out for 1 hour, followed by filtration and
the
resulting solid is washed twice in 10m1 of ethyl acetate, then dried at a
temperature of 40 C to obtain 10.2g of form II white solid; purity: 99.8%,
yield:
88.7%.
Cl elemental analysis:
Theoretically calculated value: CI content 11.91 wt%
8
CA 02829687 2013-09-10
Measured value: Cl content 11.86 wt%
Determination of crystal water content of agomelatine compound of formula
(II):
The calculated theoretical crystal water content of C15H17NO2.HC1=1420 is
6.06 wt%.
5.1 The Fischer method (Chinese Pharmacopoeia 2010 edition, appendix
VIII M)
The product resulting from embodiment 5 was measured according to the
Fischer method as mentioned above, and the crystal water content recorded was:
6.15 wt %.
5.2 Thermogravimetric analysis (Chinese Pharmacopoeia 2010 edition,
appendix VIII Q)
The product resulting from embodiment 5 was measured according to
thermogravimetric analysis as mentioned above, and the loss of crystal water
recorded was: 6.67 wt %, i.e. the crystal water content of the original
product was
6.67 wt %. For TGA curve, please refer to Figure 3.
Embodiment 6: Agomelatine compound of formula (III)
100g of agomelatine is stirred and dissolved in 800m1 of ethyl acetate. At a
low temperature an aqueous solution of HBr (8.32 g, 40%) is added dropwise and
then agitated for 1 hour before being filtered. The resulting solid is then
washed
twice in 100m1 of ethyl acetate, then dried at a temperature of 40 C to obtain
120g of white solid; purity 99.9%, yield: 85.3%.
Analysis results (C15H17NO2-HBr-H20)
Calculated value: Br% (23.35%)
Measured value: Br% (23.29%)
Determination of crystal water content of agomelatine compound of formula
(III):
The calculated theoretical crystal water content of C15H17NO2.HBr.1120 is
5.26 wt%.
6.1 The Fischer method (Chinese Pharmacopoeia 2010 edition, appendix
VIII M)
The product resulting from embodiment 6 was measured according to the
Fischer method as mentioned above, and the crystal water content recorded was:
5.10 wt %.
6.2 Thermogravimetric analysis (Chinese Pharmacopoeia 2010 edition,
appendix VIII Q)
The product resulting from embodiment 6 was measured according to
thermogravimetric analysis as mentioned above, and the loss of crystal water
recorded was: 5.70 wt %, i.e. the crystal water content of the original
product was
5.70 wt %. For TGA curve, please refer to Figure 4.
9
CA 02829687 2013-09-10
Embodiment 7: Preparation of pharmaceutical composition
1000 capsules prescribed (dosage: 25mg)
Crystalline form VII 25g
Lactose (Spherolac 100) 88.9g
Magnesium stearate 1.7g
Starch (Starch 1500) 25.5g
Sodium carboxymethyl 8.5g
starch (CMS-Na)
Ac-Di-Sol (FMC) 17g
Stearic acid 3.4g
